Semax
Semax: a synthetic peptide used clinically in Russia, its FDA status after the July 2026 advisory vote, the small human studies and the safety unknowns.
Not FDA-approved · Evidence grade C · Reviewed
Not approved by the FDA for human use. Not for human consumption. This page describes Semax only to explain its regulatory status, what has been studied and its known risks. Drawline does not recommend obtaining or using it. Disclaimer
2026 updateOctober 30, 2026: HHS published a draft policy saying it does not intend to take action against pharmacies and physicians that compound certain peptides under set conditions while FDA decides through rulemaking. It is a decision not to enforce, not approval, and it can be withdrawn.See every change in the 2026 tracker ›- Under FDA review, not approvedStroke recoveryAdvisory vote for compounding for cerebral ischemia, not approval
- Under FDA review, not approvedMigraine and nerve painAdvisory vote for compounding for migraine and trigeminal neuralgia, not approval
- Not approvedFocus and memoryPromoted for focus; not approved
Semax (ACTH(4-10) analog). Synthetic peptide.
CNot FDA-approved. Evidence grade C: limited, early or dated human data.
What is Semax?
Semax is a synthetic seven-amino-acid peptide built from a fragment of ACTH, a pituitary hormone, with three amino acids added. It is promoted for focus and memory and has been studied in Russia after stroke.
Is Semax FDA-approved?
Not approved for any use in the United States, and not a component of any FDA-approved drug. FDA notes it is a registered drug in Russia, as nasal drops. FDA had listed it among bulk substances that may present significant safety risks in compounding. The nomination was later withdrawn, and in 2026 FDA moved it to a table of withdrawn nominations while keeping its safety notes. Leaving that list does not make it approved or eligible for compounding. In July 2026 an FDA advisory committee voted to recommend adding it to the list of substances pharmacies may compound, against the advice of FDA staff. The vote is advisory. In October 2026 HHS published a draft policy saying it does not intend to take action against pharmacies and physicians that compound it under set conditions while FDA decides through rulemaking. That is a decision not to enforce, not approval, and it can be withdrawn.
What does the evidence show for Semax?
Small Russian studies after stroke: one of 30 treated patients compared with 80 others in 1997, and one of 110 patients in 2018. Neither describes randomization or blinding. There are no trials outside Russia, and most of the research is in animals and cells.
What are the known risks of Semax?
FDA says there is little or no information about its safety in people, and flags possible immune reactions and impurities. Sport: it is not named on the World Anti-Doping Code Prohibited List. The list also bans unapproved substances in general, and from 2027 names unapproved peptides there, so athletes should check with their anti-doping agency.
How is Semax measured?
Usually sold as a nasal spray or as a powder vial. For a vial, the Mix mode shows the arithmetic. Products sold online as "research use only" have no assurance of identity, dose or sterility. The calculator can do the arithmetic for any vial, but it cannot tell you what is actually in one.
Sources: FDA: Semax briefing document, July 2026; FDA: bulk drug substances that may present significant safety risks; FDA: Pharmacy Compounding Advisory Committee, July 23 and 24, 2026; HHS: enforcement discretion policy for compounding certain peptides (draft); Federal Register: HHS draft peptide compounding policy, October 30, 2026; Semax in acute ischemic stroke (1997); Gusev et al., Semax after stroke (2018); WADA: 2026 Prohibited List; USADA: athlete advisory on the 2027 Prohibited List. This profile does not recommend any dose or use.
For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.
Keep reading
Spot a mistake or an out-of-date fact? Report an error. We check every report against the sources.